Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

SHSE:688076 Stock Report

Market Cap: CN¥11.4b

Jiangsu Sinopep-Allsino Biopharmaceutical Past Earnings Performance

Past criteria checks 4/6

Jiangsu Sinopep-Allsino Biopharmaceutical has been growing earnings at an average annual rate of 32.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 26.6% per year. Jiangsu Sinopep-Allsino Biopharmaceutical's return on equity is 16.1%, and it has net margins of 26.7%.

Key information

32.7%

Earnings growth rate

24.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate26.6%
Return on equity16.1%
Net Margin26.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 04
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Recent updates

Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?

Sep 26
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jun 23
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 04
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump

Mar 04
There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump

Revenue & Expenses Breakdown

How Jiangsu Sinopep-Allsino Biopharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688076 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,576421339212
30 Jun 241,464348324196
31 Mar 241,181208300171
31 Dec 231,034163273125
30 Sep 23979168255105
30 Jun 2378413622076
31 Mar 2372513420777
31 Dec 2265112919369
30 Sep 225769518168
30 Jun 226039917465
31 Mar 226129216361
31 Dec 2164411515263
30 Sep 2164211315162
30 Jun 2166012613966
31 Mar 2168715913666
31 Dec 2056712312261
30 Sep 204819411252
30 Jun 20425749450
31 Mar 20353469345
31 Dec 19372498948
30 Sep 19313407956
30 Jun 19266318347
31 Mar 19298597439
31 Dec 18256447235
30 Sep 18284667129
30 Jun 18286716325
31 Mar 18245465623
31 Dec 17229425418
30 Sep 17156-7637
30 Jun 17104-46794
31 Mar 1726-66750
31 Dec 169-75720
30 Sep 166-53520
30 Jun 163-33310
31 Mar 166-32290
31 Dec 159-30270
31 Dec 140-25190

Quality Earnings: 688076 has a high level of non-cash earnings.

Growing Profit Margin: 688076's current net profit margins (26.7%) are higher than last year (17.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688076's earnings have grown significantly by 32.7% per year over the past 5 years.

Accelerating Growth: 688076's earnings growth over the past year (151.4%) exceeds its 5-year average (32.7% per year).

Earnings vs Industry: 688076 earnings growth over the past year (151.4%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 688076's Return on Equity (16.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 17:49
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wanhua WuChina International Capital Corporation Limited
Shitong HanCitic Securities Co., Ltd.
Jiabo ZhangGuosen Securities Co., Ltd.